Walleye Capital’s Bristol-Myers Squibb BMY Stock Holding History

Walleye Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1M	Sell	193,400 -63,100	-25%	-$3.62M	0.04%	428
2026 Q1	$15.6M	Sell	256,500 -65,000	-20%	-$3.79M	0.06%	263
2025 Q4	$17.3M	Sell	321,500 -200	-0.1%	-$9.62K	0.05%	355
2025 Q3	$14.5M	Buy	321,700 +178,500	+125%	+$8.34M	0.05%	378
2025 Q2	$6.63M	Sell	143,200 -180,200	-56%	-$8.85M	0.03%	709
2025 Q1	$19.7M	Buy	323,400 +193,900	+150%	+$11.3M	0.09%	213
2024 Q4	$7.32M	Sell	129,500 -164,000	-56%	-$9.16M	0.02%	830
2024 Q3	$15.2M	Sell	293,500 -142,300	-33%	-$6.68M	0.03%	467
2024 Q2	$18.1M	Buy	435,800 +121,300	+39%	+$5.43M	0.03%	410
2024 Q1	$17.1M	Sell	314,500 -76,500	-20%	-$3.9M	0.03%	513
2023 Q4	$20.1M	Buy	391,000 +249,000	+175%	+$13.1M	0.04%	325
2023 Q3	$8.24M	Sell	142,000 -125,800	-47%	-$7.71M	0.02%	681
2023 Q2	$17.1M	Buy	267,800 +182,300	+213%	+$12.2M	0.06%	205
2023 Q1	$5.93M	Buy	85,500 +53,700	+169%	+$3.79M	0.09%	279
2022 Q4	$2.29M	Sell	31,800 -8,600	-21%	-$648K	0.04%	515
2022 Q3	$2.87M	Buy	+40,400	New	+$2.93M	0.05%	385
2020 Q1	–	Sell	-33,900	Closed	-$2.18M	–	969
2019 Q4	$2.18M	Sell	33,900 -132,600	-80%	-$7.59M	0.14%	173
2019 Q3	$8.44M	Buy	166,500 +57,000	+52%	+$2.68M	0.5%	19
2019 Q2	$4.97M	Buy	109,500 +106,300	+3,322%	+$4.95M	0.55%	13
2019 Q1	$153K	Buy	+3,200	New	+$159K	0.03%	881

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Walleye Capital's BMY Position: Q2 2026 in Review

Walleye Capital increased its Bristol-Myers Squibb (BMY) stake by 23,085% in Q2 2026, buying an estimated $1.03M and bringing the position to 18,084 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2081.

Walleye Capital first reported a position in BMY in Q1 2019 and has held it in 18 quarters since. The position peaked at $13M in Q3 2023. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Walleye Capital held 18,084 shares of Bristol-Myers Squibb worth $1.04M as of Q2 2026.
Walleye Capital bought 18,006 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.03M.
Bristol-Myers Squibb made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2081 holding.
Walleye Capital first reported a position in Bristol-Myers Squibb in Q1 2019 and has held it in 18 quarters since.
Walleye Capital's Bristol-Myers Squibb position peaked at $13M in Q3 2023.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.